Vantrexa · NSCLC · France · Radiation oncologist · captured by Rachel Adeyemi on 23 Mar 2026 · reviewed by Dr. Elena Moretti on 24 Mar 2026
Marked as duplicate
Verbatim as captured; never edited
Radiation oncologist at Gustave Roussy raised pd-l1 testing turnaround during a congress meeting. They requested supporting literature and a follow-up discussion.
Human-approved by Dr. Elena Moretti on 24 Mar 2026
PD-L1 testing turnaround: gap in current materials reported by radiation oncologist (FR).
helixor-private-llm-2026.05 · generated 23 Mar 2026, 10:00 UTC
AI summary
PD-L1 testing turnaround raised by radiation oncologist; relevant for Medical Communications.
Source spans used by the model
Radiation oncologist at Gustave Roussy raised pd-l1 testing turnaround during a congress meeting. They requested supporting literature and a follow-up discussion.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Competitor activity | Competitor activity |
| Function | Medical Communications | Medical Communications |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 2 | 20% | 8.0 |
| Strategic alignment | 2 | 20% | 8.0 |
| Scientific importance | 1 | 15% | 3.0 |
| Urgency | 4 | 15% | 12.0 |
| Novelty | 5 | 10% | 10.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 5 | 5% | 5.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | Medium 56 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
21 Mar 2026 · Dr. Hiroshi Zimmermann, Gustave Roussy · MSL Rachel Adeyemi
Insight
Reviewed 24 Mar 2026 by Dr. Elena Moretti
Action
Initiative
Decision
Outcome
Closure
Incorporated into evidence-generation plan.
Duplicate of INS-0039 — Interest in IIS on lumevarin in chronic migraine with medication-overuse headache; population under-represented in trials.